Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Revance Reports Fourth Quarter and Full Year 2020 Financial Results
February 22, 2021 4:05 PM ESTFourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million Exited 2020 with over $200 million in annualized HintMD processing volume Cash, cash equivalents and short-term investments balance of $436.5 million at year-end, with cash into 2024 Today announced positive data from JUNIPER Phase 2 Trial of DaxibotulinumtoxinA for Injection for adult upper limb spasticity Conference call and webcast today at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More
